Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
334 Results for "
isolate
" in MedChemExpress (MCE) Product Catalog:
Products (334)
334 Results for "isolate" in MCE Product Catalog:
Cat. No.: HY-183872
CAS No.: 851075-79-1
Target:
Research Areas:
FTR1335 is an Antifungal agent as well as a selective, substrate peptide-competitive, and myristoyl-CoA non-competitive inhibitor of N-myristoyltransferase CaNmt, with an IC50 of 0.49 nM against Candida albicans CaNmt. FTR1335 exhibits fungicidal activity against Candida albicans and inhibits the growth of Candida tropicalis. FTR1335 can be used in research related to Candida albicans infections .
Cat. No.: HY-175724
Target:
Research Areas:
MBL-IN-6 (Compound 6d) is a Metallo-β-lactamase (MBL) inhibitor with Kis of 2.6 and 0.08 μM for NDM-1 and VIM-2, respectively. MBL-IN-6 has a synergistic activities with Imipenem (HY-B1369A) on MBL-producing clinical isolates (such as E. coli SI-M001, K. pneumonia T2301 and S. marcescens SI-1591) with MICs of 2-64 μg/mL. MBL-IN-6 does not have off-target effects without ACE-1 inhibition activity. MBL-IN-6 can be used for antimicrobial resistance research .
Cat. No.: HY-N10834
CAS No.: 120166-71-4
Target:
Cat. No.: HY-185443
CAS No.: 1922152-04-2
Research Areas:
UCP1172 is an antibacterial (Antibacterial) agent and Dihydrofolate reductase inhibitor, with an IC50 of 0.0089 μM against Staphylococcus aureus DfrB, 0.22 μM against DfrG, 0.41 μM against DfrA, and 0.030 μM against DfrK. UCP1172 potently inhibits the growth of MRSA/MSSA isolates carrying dfrG and dfrK (MIC values of 0.3125-0.625 μg/mL), shows weak activity against MRSA carrying dfrA (MIC of 5 μg/mL), and exerts extremely potent inhibitory effects on wild-type S. aureus ATCC 43300 (MIC of 0.0098 μg/mL). UCP1172 can be used in studies related to tuberculosis and Staphylococcus aureus infections .
Cat. No.: HY-N12931F
Cat. No.: HY-N21550
CAS No.: 1292294-32-6
Synonyms: Tricin 4'-O-(threo-β-guaiacylglyceryl)ether
Cat. No.: HY-N3185
CAS No.: 86537-66-8
Target:
Cat. No.: HY-103078A
CAS No.: 1644644-89-2
Target:
Research Areas:
I-XW-053 sodium is a specific anti-HIV-1 capsid inhibitor (IC50=164.2 μM). By binding to the CA NTD-NTD hexamerization interface and the R173 region of CTD (Kd=66.3 μM), I-XW-053 sodium disrupts capsid function and reduces polymerization levels. I-XW-053 sodium effectively blocks HIV-1 uncoating, inhibits reverse transcription and early replication, and exhibits broad-spectrum activity against primary HIV-1 isolates in peripheral blood mononuclear cells. I-XW-053 sodium can be widely used in studies related to HIV-1 infection .
Cat. No.: HY-111964R
CAS No.: 2189684-44-2
Synonyms: GS-6207 (Standard)
Target:
Research Areas:
Lenacapavir (Standard) is the analytical standard of Lenacapavir (HY-111964). This product is intended for research and analytical applications. Lenacapavir (GS-6207) is an HIV-1 capsid inhibitor. Lenacapavir binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .
Cat. No.: HY-117845
CAS No.: 122535-63-1
Synonyms: LL-E19085α
Category:
Target:
Cat. No.: HY-180191
Research Areas:
Anti-MRSA agent 42 (Compound 6d) is an anti-methicillin-resistant Staphylococcus aureus (MRSA) agent. Anti-MRSA agent 42 shows strong inhibitory effects on MRSA standard strains and 11 clinical isolates with MIC values of 0.25-0.5 μg/mL. Anti-MRSA agent 42 has low hemolytic activity and minimal cytotoxicity toward mammalian cells. Anti-MRSA agent 42 can suppress biofilm formation, compromise the cell wall, and disrupt the cytoplasmic membrane, which are accompanied by membrane depolarization, enhanced permeability, and loss of membrane integrity. Anti-MRSA agent 42 can induce ROS production and bind to DNA grooves, interfering with nucleic acid function. Anti-MRSA agent 42 can be used for the research of MRSA infection .
Cat. No.: HY-181286
Target:
Research Areas:
ETX1975-3 is an orally active inhibitor and bactericide targeting the bd cytochrome oxidase of Mycobacterium tuberculosis. ETX1975-3 disrupts electron transfer between the b-heme centers of the target enzyme, and in combination with Q203 (HY-101040), exerts bactericidal activity against both replicating and non-replicating Mycobacterium tuberculosis, and reduces bacterial loads in acute mouse models. ETX1975-3 retains activity against clinical isolates of multidrug-resistant/extensively drug-resistant Mycobacterium tuberculosis and non-tuberculous mycobacteria, while possessing favorable preclinical ADMET properties. ETX1975-3 can be used in studies related to tuberculosis and non-tuberculous mycobacterial infections .
Cat. No.: HY-187518
CAS No.: 3134912-65-2
Target:
Research Areas:
NMT-IN-9 is an arylpyrrolidone-based NMT inhibitor with an IC50 of 93.20 nM and a KD of 5.57 × 10 -9 M against NMT. NMT-IN-9 exhibits broad-spectrum antifungal activity against Candida albicans, Candida glabrata, Candida tropicalis, Cryptococcus neoformans and Aspergillus fumigatus, with an MIC of 2-16 μg/mL, and retains activity against fluconazole-resistant Candida isolates, with an MIC of 8-16 μg/mL. NMT-IN-9 induces intracellular ROS accumulation, mitochondrial membrane depolarization, DNA damage, apoptosis and necrotic cell death in fungal cells, and disrupts fungal cell integrity. NMT-IN-9 can be used for studies on NMT-targeted antifungal mechanisms and fluconazole-resistant Candida infections .
Cat. No.: HY-N19401
CAS No.: 36001-47-5
Cat. No.: HY-P990158
Target:
Research Areas:
Cat. No.: HY-111964S1
Synonyms: GS-6207-d5
Cat. No.: HY-178949
Target:
Research Areas:
MRSA antibiotic 3 (Compound C8) is a small-molecule antibiotic active against Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA), showing a MIC of 0.5 μg/mL against the standard S. aureus strain (ATCC 29213). MRSA antibiotic 3 potently inhibits the ATPase activity of S. aureus DNA gyrase with an IC50 of 0.32 μM. MRSA antibiotic 3 exhibits strong inhibitory activity against five clinical MRSA isolates, with MIC values ranging from 0.5 to 1 μg/mL. MRSA antibiotic 3 demonstrates negligible cytotoxicity at effective antibacterial concentrations and causes no hemolysis in erythrocytes even at extremely high concentrations. MRSA antibiotic 3 shows significant protective effects in both Galleria mellonella infection and murine sepsis models .
Cat. No.: HY-184981
CAS No.: 2243516-99-4
Urease-IN-24 is a cryptococcal urease inhibitor with a IC50 of 89.96 nM and a Ki of 64.3 nM. Urease-IN-24 acts as a competitive nickel-coordinating inhibitor that coordinates with the nickel center at the catalytic site of the enzyme via its carbonyl group. Urease-IN-24 reduces the capsule thickness of Cryptococcus neoformans and Cryptococcus gattii, increases cell membrane permeability, and inhibits melanin production. Urease-IN-24 exhibits fungicidal activity against Cryptococcus species. Urease-IN-24 can be used in the research of cryptococcosis .
Cat. No.: HY-182675
CAS No.: 2292113-87-0
Target:
Research Areas:
Antibiotic adjuvant 5 (Compound 2) acts as an Antibiotic adjuvant. Antibiotic adjuvant 5 enhances the activity of Azithromycin (HY-17506), Clarithromycin (HY-17508), Doripenem (HY-B0187) and Rifampin (HY-B0272) against *Pseudomonas aeruginosa* PAO1. When used in combination with Azithromycin, Antibiotic adjuvant 5 increases the survival rate of *Galleria mellonella* during *Pseudomonas aeruginosa* PAO1 infection. Antibiotic adjuvant 5 is applicable for the research of *Pseudomonas aeruginosa* infection .
Cat. No.: HY-187213
Research Areas:
Anti-MRSA agent 45 is a dihydrofolate reductase (DHFR) inhibitor and membrane-disrupting agent. Anti-MRSA agent 45 disrupts MRSA membrane integrity, increases membrane permeability and induces bacterial morphological damage. Anti-MRSA agent 45 exerts rapid, time- and concentration-dependent bactericidal activity against MRSA, and inhibits MRSA biofilm formation. Anti-MRSA agent 45 is applicable to research related to MRSA infection .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
